Anti-COVID-19 & SARS-CoV S glycoprotein [CR3022]

Catalogue Number: AB01680-49.0-ABA

Manufacturer:	Vector Laboratories, Inc (ABA)
Type:	Recombinant Monoclonal
Alias:	Spike protein; COVID19; COVID 19; S protein; SARS-CoV S protein; S glycoprotein; E2; Peplomer protein; Spike protein S1; SARS Coronavirus; SARS-CoV-2; SARS CoV 2; 2019-nCoV; Ab1680.10; Ab1680.15; Ab1680.16
Shipping Condition:	Blue Ice
Unit(s):	50 ug
Host name:	Ferret
Clone:	CR3022
Isotype:	IgM
Immunogen:	The original monoclonal antibody was generated through an scFv library derived from a peripheral blood lymphocytes of a patient exposed to the SARS-CoV.
Application:	ELISA, IF, NT, SPR, Crstapy

Overview
Datasheets

Additional Text

Uniprot ID

P59594

Purification

Purified

Antibody Clonality

Recombinant Monoclonal

Storage Note

Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.

Application Notes

This antibody binds to both SARS-CoV and SARS-CoV-2 with high affinity (PMID: 16796401 & 32065055). The initial characterization of the binding of this antibody was performed by ELISA and indicates potential for the development of diagnostic assays, as both virus-capture assays, or as controls in serological assays measuring immune-responses to virus exposure. Human IgG1, IgG3, IgM and IgA isotypes are available to mimic antibody responses seen in COVID19 (Amanat et al. 2020). Human IgG2 and IgG4 subtypes, which are also seen in a small subset of COVID-19 patients, are also available to investigate their role in the response to SARS-CoV-2. The original human IgG1 version of the antibody works synergistically in combination with another non-ompeting SARS antibody CR3014 and is a potential candidate for passive immune prophylaxis of SARS-CoV infection (Meulen et al., 2006). The original antibody (human IgG1) was also reported to bind the 2019-nCoV RBD (KD of 6.3 nM). This antibody has been attributed a potential to be developed as a therapeutic agent, alone or in combination with other neutralizing antibodies for treatment of 2019-nCoV infections (Tian et al., 2020). Bates et al. 2021 (PMID: 32766589) used CR3022 in a immunofluorescence assay.

Short Description

This chimeric ferret antibody was made using the variable domain sequences of the original Human format, for improved compatibility with existing reagents, assays and techniques.

AB01680-49.0 Datasheet

Price

£515.00

-

Quantity
Unit Size

Find out about delivery